FluGen, Inc.

FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. The M2SR Vaccine Platform has the potential to revolutionize the $5 billion annual influenza market, with a clinically-tested vaccine candidate that addresses the most significant unmet needs in flu prevention – consistent efficacy, annual virus drift, and shedding. FluGen is a Madison, Wisconsin-based company focused on the prevention and treatment of both seasonal and pandemic influenza worldwide.